Published in J Clin Invest on May 01, 1995
Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol (2009) 7.89
Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev (2005) 5.69
A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol (1998) 4.79
Enteric bacterial toxins: mechanisms of action and linkage to intestinal secretion. Microbiol Rev (1996) 3.46
Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol (2009) 1.97
Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut (1997) 1.96
Clostridium difficile toxins disrupt epithelial barrier function by altering membrane microdomain localization of tight junction proteins. Infect Immun (2001) 1.85
p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J Clin Invest (2000) 1.68
Cytoskeletal effects induced by pet, the serine protease enterotoxin of enteroaggregative Escherichia coli. Infect Immun (1999) 1.65
Characterization of a cell surface protein of Clostridium difficile with adhesive properties. Infect Immun (2001) 1.64
Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun (1998) 1.63
Neurokinin-1 (NK-1) receptor is required in Clostridium difficile- induced enteritis. J Clin Invest (1998) 1.57
Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun (1999) 1.50
Rho proteins play a critical role in cell migration during the early phase of mucosal restitution. J Clin Invest (1997) 1.40
Toxins A and B from Clostridium difficile differ with respect to enzymatic potencies, cellular substrate specificities, and surface binding to cultured cells. J Clin Invest (1997) 1.39
Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun (1996) 1.37
The role of toxin A and toxin B in Clostridium difficile-associated disease: Past and present perspectives. Gut Microbes (2010) 1.37
Clostridium difficile Toxin B causes epithelial cell necrosis through an autoprocessing-independent mechanism. PLoS Pathog (2012) 1.34
Multicenter clinical evaluation of the portrait toxigenic C. difficile assay for detection of toxigenic Clostridium difficile strains in clinical stool specimens. J Clin Microbiol (2012) 1.34
gp96 is a human colonocyte plasma membrane binding protein for Clostridium difficile toxin A. Infect Immun (2008) 1.30
Rabbit sucrase-isomaltase contains a functional intestinal receptor for Clostridium difficile toxin A. J Clin Invest (1996) 1.26
GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother (2001) 1.25
Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun (1999) 1.25
Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun (2001) 1.23
Toward a structural understanding of Clostridium difficile toxins A and B. Front Cell Infect Microbiol (2012) 1.22
Antibody-enhanced, Fc gamma receptor-mediated endocytosis of Clostridium difficile toxin A. Infect Immun (2009) 1.21
Rho GTPases dictate the mobility of the Na/H exchanger NHE3 in epithelia: role in apical retention and targeting. Proc Natl Acad Sci U S A (2005) 1.20
Neurotensin is a proinflammatory neuropeptide in colonic inflammation. J Clin Invest (1999) 1.20
Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A. Infect Immun (1999) 1.20
Corticotropin-releasing hormone (CRH) requirement in Clostridium difficile toxin A-mediated intestinal inflammation. Proc Natl Acad Sci U S A (2004) 1.19
Bacteroides fragilis toxin 2 damages human colonic mucosa in vitro. Gut (1999) 1.18
Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun (2003) 1.18
Clostridium difficile infection. Am J Med Sci (2010) 1.17
Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob Agents Chemother (1996) 1.17
Models for the study of Clostridium difficile infection. Gut Microbes (2012) 1.16
Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun (2001) 1.15
Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig Dis Sci (2010) 1.13
Clostridium difficile infection in the twenty-first century. Emerg Microbes Infect (2013) 1.09
Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Antimicrob Agents Chemother (1997) 1.07
The enterotoxicity of Clostridium difficile toxins. Toxins (Basel) (2010) 1.07
Clostridium difficile cell attachment is modified by environmental factors. Appl Environ Microbiol (1999) 1.03
Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. Vaccine (2008) 1.03
A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model. Clin Vaccine Immunol (2013) 1.03
Persistence and toxin production by Clostridium difficile within human intestinal organoids result in disruption of epithelial paracellular barrier function. Infect Immun (2014) 1.01
Clostridium difficile infection. Nat Rev Dis Prim (2016) 0.99
Structural determinants of Clostridium difficile toxin A glucosyltransferase activity. J Biol Chem (2012) 0.99
Essential role of the glucosyltransferase activity in Clostridium difficile toxin-induced secretion of TNF-alpha by macrophages. Microb Pathog (2009) 0.99
Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship. World J Gastroenterol (2010) 0.97
The effect of nutrition on intestinal epithelial barrier function. Ann Surg (1996) 0.97
Clostridium difficile toxin A decreases acetylation of tubulin, leading to microtubule depolymerization through activation of histone deacetylase 6, and this mediates acute inflammation. J Biol Chem (2010) 0.97
Early effects of catecholamine therapy on mucosal integrity, intestinal blood flow, and oxygen metabolism in porcine endotoxin shock. Ann Surg (1998) 0.97
Nitric oxide donating compounds stimulate human colonic ion transport in vitro. Gut (1996) 0.96
Regulation of Apoptosis by Gram-Positive Bacteria: Mechanistic Diversity and Consequences for Immunity. Curr Immunol Rev (2006) 0.96
Clostridium difficile infection in the intensive care unit. Infect Dis Clin North Am (2009) 0.93
Monocytes are highly sensitive to clostridium difficile toxin A-induced apoptotic and nonapoptotic cell death. Infect Immun (2005) 0.90
Recent emergence of an epidemic clindamycin-resistant clone of Clostridium difficile among Polish patients with C. difficile-associated diarrhea. J Clin Microbiol (2003) 0.90
Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes. Antimicrob Agents Chemother (2013) 0.89
Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure. Infect Immun (2012) 0.89
Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea. Biophys J (2004) 0.89
Clostridium difficile: epidemiology, diagnostic and therapeutic possibilities-a systematic review. Tech Coloproctol (2013) 0.89
Clostridium difficile toxin A binds colonocyte Src causing dephosphorylation of focal adhesion kinase and paxillin. Exp Cell Res (2009) 0.88
Clostridium difficile-associated colitis. Can Fam Physician (2004) 0.88
Recognition and prevention of hospital-associated enteric infections in the intensive care unit. Crit Care Med (2010) 0.88
The involvement of macrophage-derived tumour necrosis factor and lipoxygenase products on the neutrophil recruitment induced by Clostridium difficile toxin B. Immunology (1997) 0.87
Clostridium difficile-associated Enteric Disease. Curr Infect Dis Rep (2002) 0.86
Essential role of toxin A in C. difficile 027 and reference strain supernatant-mediated disruption of Caco-2 intestinal epithelial barrier function. Clin Exp Immunol (2008) 0.84
Immune-based treatment and prevention of Clostridium difficile infection. Hum Vaccin Immunother (2014) 0.84
Primary human colonic myofibroblasts are resistant to Clostridium difficile toxin A-induced, but not toxin B-induced, cell death. Infect Immun (2011) 0.83
Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection. Antimicrob Agents Chemother (2009) 0.82
Theodore E. Woodward Award. How bacterial enterotoxins work: insights from in vivo studies. Trans Am Clin Climatol Assoc (2002) 0.82
Systems analysis of the transcriptional response of human ileocecal epithelial cells to Clostridium difficile toxins and effects on cell cycle control. BMC Syst Biol (2012) 0.82
Systems Modeling of Interactions between Mucosal Immunity and the Gut Microbiome during Clostridium difficile Infection. PLoS One (2015) 0.81
Clostridium difficile infection of the gut. J Clin Pathol (1996) 0.81
Glutamine and alanyl-glutamine increase RhoA expression and reduce Clostridium difficile toxin-a-induced intestinal epithelial cell damage. Biomed Res Int (2012) 0.80
Evaluation of a new enzyme immunoassay for Clostridium difficile toxin A. J Clin Pathol (1997) 0.80
Clostridial toxins: sensing a target in a hostile gut environment. Gut Microbes (2012) 0.80
Lactobacillus rhamnosus L34 and Lactobacillus casei L39 suppress Clostridium difficile-induced IL-8 production by colonic epithelial cells. BMC Microbiol (2014) 0.79
Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review. Curr Top Med Chem (2014) 0.79
Using phenotype microarrays to determine culture conditions that induce or repress toxin production by Clostridium difficile and other microorganisms. PLoS One (2013) 0.79
Involvement of nerves and calcium channels in the intestinal response to Clostridium difficile toxin A: an experimental study in rats in vivo. Gut (2001) 0.78
The Role of Rho GTPases in Toxicity of Clostridium difficile Toxins. Toxins (Basel) (2015) 0.77
Development and Validation of Digital Enzyme-Linked Immunosorbent Assays for Ultrasensitive Detection and Quantification of Clostridium difficile Toxins in Stool. J Clin Microbiol (2015) 0.77
Initiation of an inflammatory response in resident intestinal lamina propria cells -use of a human organ culture model. PLoS One (2014) 0.77
Clostridium difficile Toxins A and B: Insights into Pathogenic Properties and Extraintestinal Effects. Toxins (Basel) (2016) 0.77
Clostridium difficile toxin B intoxicated mouse colonic epithelial CT26 cells stimulate the activation of dendritic cells. Pathog Dis (2015) 0.75
Effects of anti-inflammatory drugs on fever and neutrophilia induced by Clostridium difficile toxin B. Mediators Inflamm (1996) 0.75
Clostridium difficile Toxins TcdA and TcdB Cause Colonic Tissue Damage by Distinct Mechanisms. Infect Immun (2016) 0.75
Trends in Clostridium difficile Disease: Epidemiology and Intervention. Infect Med (2009) 0.75
Ultrasensitive Detection and Quantification of Toxins for Optimized Diagnosis of Clostridium difficile Infection. J Clin Microbiol (2015) 0.75
Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med (1978) 14.65
Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis (1977) 7.68
Purification and characterization of toxins A and B of Clostridium difficile. Infect Immun (1982) 6.88
Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology (1978) 5.91
Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun (1985) 5.44
Biological activities of toxins A and B of Clostridium difficile. Infect Immun (1982) 4.62
Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun (1990) 4.06
Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. J Clin Invest (1988) 3.12
Nucleotide sequence of Clostridium difficile toxin B gene. Nucleic Acids Res (1990) 2.93
Differential effects of Clostridium difficile toxins A and B on rabbit ileum. Gastroenterology (1987) 2.54
Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J Clin Invest (1994) 2.25
CP-96,345, a substance P antagonist, inhibits rat intestinal responses to Clostridium difficile toxin A but not cholera toxin. Proc Natl Acad Sci U S A (1994) 2.22
Clostridium difficile toxin B acts on the GTP-binding protein Rho. J Biol Chem (1994) 2.09
Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect Immun (1987) 2.06
Purification and properties of Clostridium difficile cytotoxin B. J Biol Chem (1986) 1.97
Effect of toxin A and B of Clostridium difficile on rabbit ileum and colon. Gut (1986) 1.93
Differential effects of Clostridium difficile toxins on tissue-cultured cells. J Clin Microbiol (1982) 1.87
Cytokine response by human monocytes to Clostridium difficile toxin A and toxin B. Infect Immun (1991) 1.87
Clostridium difficile toxin B disrupts the barrier function of T84 monolayers. Gastroenterology (1992) 1.62
Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology (1993) 1.56
Clostridium difficile toxin A and its effects on cells. Toxicon (1991) 1.54
Ultrastructural effects of Clostridium difficile toxin B on smooth muscle cells and fibroblasts. Exp Cell Res (1983) 1.46
C. difficile toxin A increases intestinal permeability and induces Cl- secretion. Am J Physiol (1990) 1.37
Mucosal damage mediated by clostridial toxin in experimental clindamycin-associated colitis. Gut (1980) 1.37
Ketotifen inhibits Clostridium difficile toxin A-induced enteritis in rat ileum. Gastroenterology (1993) 1.36
Characterization of rabbit ileal receptors for Clostridium difficile toxin A. Evidence for a receptor-coupled G protein. J Clin Invest (1991) 1.34
Enterotoxins from Clostridium difficile; diarrhoeogenic potency and morphological effects in the rat intestine. Gut (1990) 1.15
Macrophage-dependent stimulation of T cell-depleted spleen cells by Clostridium difficile toxin A and calcium ionophore. Cell Immunol (1990) 1.15
Rapid epithelial restitution of human and rabbit colonic mucosa. Gastroenterology (1989) 1.11
Clostridium difficile cytotoxin inhibits protein synthesis in fibroblasts and intestinal mucosa. Gastroenterology (1986) 1.11
Protooncogene abnormalities in colon cancers and adenomatous polyps. Gastroenterology (1987) 1.07
Binding kinetics of Clostridium difficile toxins A and B to intestinal brush border membranes from infant and adult hamsters. Infect Immun (1991) 0.97
Biochemical and pathological effects of Clostridium difficile toxins in mice. Toxicon (1982) 0.84
Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet (2001) 11.06
Clostridium difficile colitis. N Engl J Med (1994) 9.31
Clostridium difficile infection. Annu Rev Med (1998) 3.63
Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. J Clin Invest (1988) 3.12
Sleeve gastrectomy and gastric banding: effects on plasma ghrelin levels. Obes Surg (2005) 2.91
Rational approach to iron-deficiency anaemia in premenopausal women. Lancet (1999) 2.83
Acute compartment syndromes. Br J Surg (2002) 2.81
Experimental clindamycin-associated colitis in rabbits. Evidence of toxin-mediated mucosal damage. Gastroenterology (1978) 2.63
Differential effects of Clostridium difficile toxins A and B on rabbit ileum. Gastroenterology (1987) 2.54
Neuronal involvement in the intestinal effects of Clostridium difficile toxin A and Vibrio cholerae enterotoxin in rat ileum. Gastroenterology (1994) 2.28
Sacral nerve stimulation in patients with severe constipation. Dis Colon Rectum (2008) 2.25
Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J Clin Invest (1994) 2.25
Therapeutic implications of Clostridium difficile toxin during relapse of chronic inflammatory bowel disease. Lancet (1980) 2.24
CP-96,345, a substance P antagonist, inhibits rat intestinal responses to Clostridium difficile toxin A but not cholera toxin. Proc Natl Acad Sci U S A (1994) 2.22
The sand seas of Titan: Cassini RADAR observations of longitudinal dunes. Science (2006) 2.11
Provision of vascular surgery in England in 2012. Eur J Vasc Endovasc Surg (2012) 2.02
Role of gallbladder mucus hypersecretion in the evolution of cholesterol gallstones. J Clin Invest (1981) 1.99
Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut (2005) 1.99
Proteome-based plasma biomarkers for Alzheimer's disease. Brain (2006) 1.98
Purification and properties of Clostridium difficile cytotoxin B. J Biol Chem (1986) 1.97
The lakes of Titan. Nature (2007) 1.97
Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr (1991) 1.97
Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut (1997) 1.96
Trefoil peptide protection of intestinal epithelial barrier function: cooperative interaction with mucin glycoprotein. Gastroenterology (1995) 1.93
Mucin biophysics. Annu Rev Physiol (1995) 1.93
Role of substance P and the neurokinin 1 receptor in acute pancreatitis and pancreatitis-associated lung injury. Proc Natl Acad Sci U S A (1998) 1.90
A decision support system for prevention and treatment of pressure ulcers based on AHCPR guidelines. Proc AMIA Annu Fall Symp (1996) 1.83
High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. Hum Mol Genet (2001) 1.79
Increased substance P responses in dorsal root ganglia and intestinal macrophages during Clostridium difficile toxin A enteritis in rats. Proc Natl Acad Sci U S A (1997) 1.70
p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J Clin Invest (2000) 1.68
The retrojugular approach to carotid endarterectomy--a safer technique? Eur J Vasc Endovasc Surg (2005) 1.66
Molecular epidemiology of a large outbreak of hepatitis B linked to autohaemotherapy. Lancet (2000) 1.66
Studies on natural recovery from alcohol dependence: sample selection bias by media solicitation? Addiction (2000) 1.65
Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. Hepatology (1998) 1.62
Clostridium difficile toxin B disrupts the barrier function of T84 monolayers. Gastroenterology (1992) 1.62
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br J Cancer (2013) 1.57
Neurokinin-1 (NK-1) receptor is required in Clostridium difficile- induced enteritis. J Clin Invest (1998) 1.57
Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun (1999) 1.50
Improving the patency of vascular bypass grafts: the role of suture materials and surgical techniques on reducing anastomotic compliance mismatch. Eur J Vasc Endovasc Surg (2003) 1.49
Ultrastructural effects of Clostridium difficile toxin B on smooth muscle cells and fibroblasts. Exp Cell Res (1983) 1.46
Aortic aneurysm repair in a renal transplant patient: preservation of renal function. Eur J Vasc Surg (1991) 1.44
Modern management of pulmonary embolism. Br J Surg (1999) 1.44
Results of a recently instituted programme of thrombolytic therapy in acute lower limb ischaemia. Br J Surg (1991) 1.44
A comparison of para-anastomotic compliance profiles after vascular anastomosis: nonpenetrating clips versus standard sutures. J Vasc Surg (2001) 1.43
Association of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel disease. Gastroenterology (1981) 1.42
Clostridium difficile toxin A stimulates intracellular calcium release and chemotactic response in human granulocytes. J Clin Invest (1988) 1.41
Reverse transcriptase template switching during reverse transcriptase-polymerase chain reaction: artificial generation of deletions in ribonucleotide reductase mRNA. J Lab Clin Med (2001) 1.39
Arthritis associated with intestinal-bypass procedure for morbid obesity. Complement activation and characterization of circulating cryoproteins. N Engl J Med (1976) 1.39
Acute limb ischaemia secondary to a collagen plug device. Eur J Vasc Endovasc Surg (2000) 1.39
Seeding of human microvascular endothelial cells onto polytetrafluoroethylene graft material. Br J Surg (1991) 1.39
Treatment of gastrointestinal infections. Gastroenterology (2000) 1.39
Medical rubber anaphylaxis. Lancet (1990) 1.38
Vacuum drainage of groin wounds after vascular surgery. Br J Surg (1990) 1.38
Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun (1996) 1.37
A multicenter review of carotid body tumour management. Eur J Vasc Endovasc Surg (2007) 1.37
C. difficile toxin A increases intestinal permeability and induces Cl- secretion. Am J Physiol (1990) 1.37
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol (2012) 1.37
Ketotifen inhibits Clostridium difficile toxin A-induced enteritis in rat ileum. Gastroenterology (1993) 1.36
Characterization of rabbit ileal receptors for Clostridium difficile toxin A. Evidence for a receptor-coupled G protein. J Clin Invest (1991) 1.34
Aspirin prevention of cholesterol gallstone formation in prairie dogs. Science (1981) 1.34
Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding. Gastroenterology (1992) 1.32
Human gallbladder mucin accelerates nucleation of cholesterol in artificial bile. Gastroenterology (1984) 1.32
Human colon cancer cells express ICAM-1 in vivo and support LFA-1-dependent lymphocyte adhesion in vitro. Am J Physiol (1992) 1.32
Toxic megacolon. Lancet (1998) 1.31
Comparative study of Clostridium difficile toxin A and cholera toxin in rabbit ileum. Gastroenterology (1989) 1.30
Signal transduction pathways mediating neurotensin-stimulated interleukin-8 expression in human colonocytes. J Biol Chem (2001) 1.29
Atherosclerotic renovascular disease causing renal impairment--a case for treatment. Clin Nephrol (1989) 1.28
Diminished Clostridium difficile toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor. J Clin Invest (1992) 1.28
Experimental colon cancer. Gastroenterology (1978) 1.27
Profound increase in viscosity and aggregation of pig gastric mucin at low pH. Am J Physiol (1991) 1.27
Involvement of Ras-related Rho proteins in the mechanisms of action of Clostridium difficile toxin A and toxin B. Infect Immun (1995) 1.26
Rabbit sucrase-isomaltase contains a functional intestinal receptor for Clostridium difficile toxin A. J Clin Invest (1996) 1.26
Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut (2005) 1.26
Clostridium difficile toxin A stimulates macrophage-inflammatory protein-2 production in rat intestinal epithelial cells. J Immunol (1998) 1.25
Direct evidence of mast cell involvement in Clostridium difficile toxin A-induced enteritis in mice. Gastroenterology (1998) 1.24
Acute stress causes mucin release from rat colon: role of corticotropin releasing factor and mast cells. Am J Physiol (1996) 1.24
Micronuclear DNA from Paramecium tetraurelia: serotype 51 A gene has internally eliminated sequences. J Protozool (1993) 1.24
In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther (2000) 1.24
pH-dependent conformational change of gastric mucin leads to sol-gel transition. Biophys J (1999) 1.23
Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma. Br J Cancer (2000) 1.22
The mechanical properties of infrainguinal vascular bypass grafts: their role in influencing patency. Eur J Vasc Endovasc Surg (2006) 1.21
Neurotensin is a proinflammatory neuropeptide in colonic inflammation. J Clin Invest (1999) 1.20
IL-8 release and neutrophil activation by Clostridium difficile toxin-exposed human monocytes. Am J Physiol (1997) 1.20